Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK29116 in Relapsed/Refractory B-Cell Malignancies
NCT04861779Phase 1Unknown
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 2
01
Overview
Phase 1, open-label trial of HSK29116 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 4 more (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Number of Participants with Protocol Specified Dose-Limiting Toxicities at 1 year, Establish MTD and/or Recommended Phase 1b Dose at 1 year and 1 more. Status: unknown.
02
Drugs
HSK29116
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04861779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861779.